The Post-Patent Cliff Tab: Pharma Battered But Still Financially Strong, Says Moody’s
This article was originally published in The Pink Sheet Daily
Executive Summary
The patent cliff has battered pharma companies’ financial underpinnings over the past three years, both directly and indirectly, but the industry is still comparatively well endowed to face new macro challenges, ranging from health care reform to pricing pressure and relentless competition, according to Moody’s.